USANA Health Sciences (NYSE:USNA) Rating Lowered to “Strong Sell” at Zacks Research

USANA Health Sciences (NYSE:USNA) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Thursday,Zacks.com reports.

Several other research analysts have also commented on the stock. Wall Street Zen lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

USANA Health Sciences Stock Up 3.6%

Shares of USNA stock opened at $15.43 on Thursday. The firm has a market cap of $284.84 million, a price-to-earnings ratio of -12.75, a PEG ratio of 1.63 and a beta of 0.73. USANA Health Sciences has a 52-week low of $14.35 and a 52-week high of $32.32. The company’s 50 day moving average is $20.41 and its 200 day moving average is $19.66.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). The company had revenue of $223.27 million for the quarter, compared to analysts’ expectations of $235.00 million. USANA Health Sciences had a positive return on equity of 3.41% and a negative net margin of 2.43%.USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Analysts anticipate that USANA Health Sciences will post 0.76 EPS for the current fiscal year.

Insider Transactions at USANA Health Sciences

In other news, insider Brent Neidig sold 5,002 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $19.45, for a total transaction of $97,288.90. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director John Turman Fleming sold 2,450 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $17.93, for a total transaction of $43,928.50. Following the completion of the transaction, the director directly owned 4,230 shares of the company’s stock, valued at $75,843.90. The trade was a 36.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 13,869 shares of company stock worth $261,441. Insiders own 0.82% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in USNA. Pzena Investment Management LLC acquired a new stake in USANA Health Sciences during the 2nd quarter worth about $25,739,000. BlackRock Inc. acquired a new position in shares of USANA Health Sciences in the second quarter valued at about $33,182,000. Deutsche Bank AG acquired a new position in shares of USANA Health Sciences in the second quarter valued at about $822,000. Bank of New York Mellon Corp purchased a new position in shares of USANA Health Sciences in the second quarter worth about $1,105,000. Finally, State of Wyoming acquired a new stake in shares of USANA Health Sciences during the second quarter worth about $242,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Key Stories Impacting USANA Health Sciences

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti raised its estimates for Q3 2026 EPS to $0.11 from $0.09, Q1 2027 EPS to $0.34 from $0.31, and Q2 2027 EPS to $0.46 from $0.43. These revisions suggest some improvement in the analyst’s near-term outlook.
• Neutral Sentiment: Wall Street Zen lowered its stock rating on USANA, adding to uncertainty around the company’s outlook. USANA Health Sciences Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: Sidoti’s broader revisions were substantially bearish: FY2026 EPS was cut to $0.76 from $2.12, FY2027 EPS to $1.77 from $2.77, and Q3 2026 EPS to $0.11 from $0.43 in the latest updates. The firm also reduced estimates for Q4 2026, Q1 2027, Q2 2027, and Q3 2027, although some of those forecasts were later partially raised.
• Negative Sentiment: The estimate cuts follow USANA’s latest quarterly results, in which the company reported a $0.07 per-share loss and revenue of $223.27 million, missing analyst expectations of $0.43 EPS and $235 million in revenue. The company’s FY2026 guidance remains just $0.76 EPS, reinforcing concerns about weak profitability and slowing business momentum.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.